DOCSLIB.ORG

A Three-Part Study to Investigate the Incidence and Potential Etiologies of Tadalafil-Associated Back Pain Or Myalgia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Three-Part Study to Investigate the Incidence and Potential Etiologies of Tadalafil-Associated Back Pain Or Myalgia International Journal of Impotence Research (2005) 17, 455–461 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia AD Seftel1*, J Farber2, J Fletcher3, MC Deeley4, A Elion-Mboussa5, A Hoover5,AYu4 and P Fredlund6 1Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, USA; 2University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; 3Division of Nuclear Medicine, Department of Radiology, Indiana University School of Medicine, Indianapolis, Indiana, USA; 4ICOS Corporation, Bothell, Washington, USA; 5Lilly Research Laboratories, Indianapolis, Indiana, USA; and 6University of Washington School of Medicine, Seattle, Washington, USA The potential mechanisms underlying back pain and/or myalgia experienced by men taking tadalafil were investigated. An integrated analysis of 10 placebo-controlled tadalafil clinical trials (N ¼ 1846) showed that the incidence of back pain and/or myalgia was 9.4% in patients receiving tadalafil 10 mg (N ¼ 394), 8.3% in patients receiving tadalafil 20 mg (N ¼ 883) and 3.7% in placebo- treated patients (N ¼ 569). One (0.3%) patient receiving tadalafil 10 mg, six (0.7%) patients receiving tadalafil 20 mg, and no patients receiving placebo discontinued treatment due to back pain and/or myalgia. In a prospective study in healthy volunteers, no substantial changes were observed in laboratory markers indicative of inflammation or muscle damage, and tadalafil did not affect renal plasma flow nor produce lumbar or gluteal myositis by positron emission tomography scan or magnetic resonance imaging. Although the mechanism of back pain and/or myalgia remains unknown, these events appear to be self-limiting and a general effect of phosphodiesterase 5 inhibition. International Journal of Impotence Research (2005) 17, 455–461. doi:10.1038/sj.ijir.3901374; published online 21 July 2005 Keywords: impotence; phosphodiesterase inhibitors; back pain; myositis Introduction In tadalafil clinical pharmacology trials, back pain or myalgia generally occurred 12–24 h after dosing and typically resolved within 48 h. The back pain Oral phosphodiesterase 5 (PDE5) inhibitors are now and myalgia associated with tadalafil treatment was standard therapeutic options for the treatment of characterized by diffuse bilateral lower lumbar, erectile dysfunction (ED). All three currently mar- gluteal, thigh, or thoracolumbar muscular discom- keted PDE5 inhibitors sildenafil citrate (sildenafil), fort, and was exacerbated by recumbency. In general, tadalafil, and vardenafil hydrochloride (vardenafil), pain was reported as mild or moderate in severity, 1–7 are effective and generally well tolerated. The and resolved with acetaminophen or nonsteroidal most common side effects of this class of medica- anti-inflammatory drugs when necessary. Severe tions include headache, flushing, dyspepsia, and back pain was reported infrequently (o5% of all rhinorrhea, the majority of which may be related to reports). Overall, approximately 0.4% of all tadala- the mild vasodilatory effects associated with PDE5 fil-treated ED patients discontinued treatment 8,9 inhibition. Back pain or myalgia have also been as a consequence of back pain or myalgia, within reported to varying degrees with each of the three the same range as discontinuations for headache 4,10–12 marketed PDE5 inhibitors. (0.8%).4 The origins of lumbar pain in general may be complex, myriad, and include structural, degenera- tive, and inflammatory processes of the spine, as *Correspondence: AD Seftel, Department of Urology, Case well as pain referred from the abdomen, pelvis, and Western Reserve University, University Hospitals of 13,14 Cleveland, Cleveland VA Medical Center, 11100 Euclid urinary tract. HMG-CoA reductase inhibitors Ave., Cleveland, OH 44106-5046, USA. have been reported to induce clinically important E-mail: [email protected] myositis or rhabdomyolysis, which may present Received 7 April 2005; accepted 20 May 2005 with back pain or myalgia.15 Tadalafil and back pain and/or myalgia AD Seftel et al 456 To investigate the nature of back pain associated severe event was counted. Patient discontinuation with tadalafil use, we first conducted a retrospective rates due to back pain and/or myalgia were analysis of the combined incidence of eight adverse summarized descriptively. event terms coded in the databases from 10 placebo- controlled studies of tadalafil for ED and possibly associated with back pain and/or myalgia. In the Part 2: PET, MRI, and radionuclide testing second part of the investigation, we prospectively conducted a clinical pharmacology study in healthy Healthy males, 18–45 y of age, were enrolled into volunteers using three radiologic examinations 18 a double-blind, two-period crossover study compar- ([ F]-fluorodeoxyglucose positron emission tomo- ing a single dose of either placebo and tadalafil graphy scan ([18F]-FDG-PET),16 gadolinium-en- 17 20 mg or placebo and tadalafil 80 mg. The periods hanced magnetic resonance imaging (MRI) scans, were separated by a 10-day washout period. Sub- and technetium mertiatide (Tc99m) scanning) to jects were resident in a Clinical Pharmacology Unit investigate whether there is a pathological process the night before dosing and through 24–30 h post- or venocongestion localized in the lumbar and dose. At 22–30 h after dosing in each period, gluteal muscles, or an underlying abnormality in radionuclide renal scan, bilateral gadolinium- renal plasma flow. In the final part, we conducted a enhanced MRI scans of the lumbar and gluteal prospective laboratory investigation to examine the muscles, and [18F]-FDG-PET scans were per- possible involvement of inflammatory or myolytic formed.20,21 The timing of these assessments corre- processes in the reports of back pain and/or myalgia. sponded to the time of peak incidence of reported The results of this investigation indicated that back pain and/or myalgia following tadalafil dosing back pain or myalgia induced by tadalafil occurs in subjects enrolled in clinical pharmacology stu- with a combined incidence of approximately 9% in dies (12–24 h post dose).10 Effective renal plasma patients with ED, and are not associated with a flow in each kidney (ml/min/1.73 m2) was assessed serious underlying pathology. by determining Tc99m clearance.22 Subjects re- turned approximately 48 h post-dose for clinical laboratory evaluations and physical examination. Patients and methods The outcome measures for the MRI scan were qualitative comparisons for the presence of fasciitis, vasculitis, myositis, abscess and lumbar and gluteal Part 1: Integrated data analysis muscle venocongestion after dosing, relative to the predose assessment. The outcome measure for FDG PET was the standardized uptake value (SUV) of We retrospectively analyzed a large database of radiolabeled glucose. The outcome measure for the patients with ED who had enrolled in one of 10 99mTc mertiatide study was effective renal plasma multicenter, randomized, placebo-controlled, dou- flow. All assessments were made by two treatment- ble-blind, efficacy, and safety studies conducted blinded qualified radiologists or nuclear medicine between November 1999 and September 2002. Nine physicians. of the 10 studies were included in the integrated All subjects who completed at least one study analysis of 11 tadalafil studies previously re- period were included in the analysis. An analysis of ported.18 The remaining study reported here en- 19 covariance (ANCOVA) model that included terms rolled men with diabetes mellitus and ED. for baseline, subject, period, and treatment was used Inclusion and exclusion criteria, study design, and to calculate the least-squares means and residual patient demographics have been described pre- variance to compute 95% confidence intervals for 18,19 Z Z viously. Briefly, men 18 y old with a 3- the post-baseline effective renal plasma flow and month history of ED were randomized to 12 weeks PET scan SUV. Categorical changes from baseline in of treatment with placebo or tadalafil taken as MRI scan data were made (worse, better, or same). needed up to once per day. Symptoms reported by Values of the same or better were pooled together patients during the clinical trials were recorded and McNemar’s test performed to test for treatment verbatim, then classified using the Medical Diction- differences. For blood flow data, values of À1 ary for Regulatory Activities (MedDRA) terminology. (decrease) and 0 (no change) were pooled together, Eight terms including back pain, myalgia, back and the McNemar’s test performed to test for stiffness, buttock pain, coccydynia, loin pain, pain treatment differences. NOS (not otherwise specified), and sacral pain were collectively referred to as ‘back pain and/or myal- gia.’ New or worsened reports of back pain and/or Part 3: Tests for inflammatory conditions myalgia reports during the study period were summarized for all randomized patients treated with placebo or tadalafil 10 or 20 mg. When a All subjects enrolled in one of five double-blind, patient reported more than one event, only the most placebo-controlled, crossover-design, clinical phar- International Journal of Impotence Research Tadalafil and back pain and/or myalgia AD Seftel et al 457 Table 1 Laboratory tests measured tadalafil 20 mg group. Overall, 25.4% of patients were 65 y or older. The patients
Load more

Recommended publications
  • Download the Herniated Disc Brochure
    AN INTRODUCTION TO HERNIATED DISCS This booklet provides general information on herniated discs. It is not meant to replace any personal conversations that you might wish to have with your physician or other member of your healthcare team. Not all the information here will apply to your individual treatment or its outcome. About the Spine CERVICAL The human spine is comprised 24 bones or vertebrae in the cervical (neck) spine, the thoracic (chest) spine, and the lumbar (lower back) THORACIC spine, plus the sacral bones. Vertebrae are connected by several joints, which allow you to bend, twist, and carry loads. The main joint LUMBAR between two vertebrae is called an intervertebral disc. The disc is comprised of two parts, a tough and fibrous outer layer (annulus fibrosis) SACRUM and a soft, gelatinous center (nucleus pulposus). These two parts work in conjunction to allow the spine to move, and also provide shock absorption. INTERVERTEBRAL ANNULUS DISC FIBROSIS SPINAL NERVES NUCLEUS PULPOSUS Each vertebrae has an opening (vertebral foramen) through which a tubular bundle of spinal nerves and VERTEBRAL spinal nerve roots travel. FORAMEN From the cervical spine to the mid-lumbar spine this bundle of nerves is called the spinal cord. The bundle is then referred to as the cauda equina through the bottom of the spine. At each level of the spine, spinal nerves exit the spinal cord and cauda equina to both the left and right sides. This enables movement and feeling throughout the body. What is a Herniated Disc? When the gelatinous center of the intervertebral disc pushes out through a tear in the fibrous wall, the disc herniates.
    [Show full text]
  • Aetiology of Fibrositis
    Ann Rheum Dis: first published as 10.1136/ard.6.4.241 on 1 January 1947. Downloaded from AETIOLOGY OF FIBROSITIS: A REVIEW BY MAX VALENTINE From a review of systems of classification of fibrositis (National Mineral Water Hospital, Bath, 1940; Devonshire Royal Hospital, Buxton, 1940; Ministry of Health Report, 1924; Harrogate Royal Bath Hospital Report, 1940; Ray, 1934; Comroe, 1941 ; Patterson, 1938) the one in use at the National Mineral Water Hospital, Bath, is considered most valuable. There are five divisions of fibrositis as follows: (a) intramuscular, (b) periarticular, (c) bursal and tenosynovial, (d) subcutaneous, (e) perineuritic, the latter being divided into (i) brachial (ii) sciatic, etc. Laboratory Tests No biochemical abnormalities have been demonstrated in fibrositis. Mester (1941) claimed a specific test for " rheumatism ", but Copeman and Stewart (1942) did not find it of value and question its rationale. The sedimentation rate is usually normal or may be slightly increased; this is confirmed by Kahlmeter (1928), Sha;ckle (1938), and Dawson and others (1930). Miller copyright. and Gibson (1941) found a slightly increased rate in 52-3% of patients, and Collins and others (1939) found a (usually) moderately increased rate in 35% of cases tested. Case Analyses In an investigation Valentine (1943) found an incidence of fibrositis of 31-4% (60% male) at a Spa hospital. (Cf. Ministry of Health Report, 1922, 30-8%; Buxton Spa Hospital, 1940, 49 5%; Bath Spa Hospital, 1940, 22-3%; Savage, 1941, 52% in the Forces.) Fibrositis was commonest http://ard.bmj.com/ between the ages of40 and 60; this is supported by the SpaHospital Report, Buxton, 1940.
    [Show full text]
  • Guidline for the Evidence-Informed Primary Care Management of Low Back Pain
    Guideline for the Evidence-Informed Primary Care Management of Low Back Pain 2nd Edition These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. Guideline Disease/Condition(s) Targeted Specifications Acute and sub-acute low back pain Chronic low back pain Acute and sub-acute sciatica/radiculopathy Chronic sciatica/radiculopathy Category Prevention Diagnosis Evaluation Management Treatment Intended Users Primary health care providers, for example: family physicians, osteopathic physicians, chiro- practors, physical therapists, occupational therapists, nurses, pharmacists, psychologists. Purpose To help Alberta clinicians make evidence-informed decisions about care of patients with non- specific low back pain. Objectives • To increase the use of evidence-informed conservative approaches to the prevention, assessment, diagnosis, and treatment in primary care patients with low back pain • To promote appropriate specialist referrals and use of diagnostic tests in patients with low back pain • To encourage patients to engage in appropriate self-care activities Target Population Adult patients 18 years or older in primary care settings. Exclusions: pregnant women; patients under the age of 18 years; diagnosis or treatment of specific causes of low back pain such as: inpatient treatments (surgical treatments); referred pain (from abdomen, kidney, ovary, pelvis,
    [Show full text]
  • Inflammatory Back Pain in Patients Treated with Isotretinoin Although 3 NSAID Were Administered, Her Complaints Did Not Improve
    Inflammatory Back Pain in Patients Treated with Isotretinoin Although 3 NSAID were administered, her complaints did not improve. She discontinued isotretinoin in the third month. Over 20 days her com- To the Editor: plaints gradually resolved. Despite the positive effects of isotretinoin on a number of cancers and In the literature, there are reports of different mechanisms and path- severe skin conditions, several disorders of the musculoskeletal system ways indicating that isotretinoin causes immune dysfunction and leads to have been reported in patients who are treated with it. Reactive seronega- arthritis and vasculitis. Because of its detergent-like effects, isotretinoin tive arthritis and sacroiliitis are very rare side effects1,2,3. We describe 4 induces some alterations in the lysosomal membrane structure of the cells, cases of inflammatory back pain without sacroiliitis after a month of and this predisposes to a degeneration process in the synovial cells. It is isotretinoin therapy. We observed that after termination of the isotretinoin thought that isotretinoin treatment may render cells vulnerable to mild trau- therapy, patients’ complaints completely resolved. mas that normally would not cause injury4. Musculoskeletal system side effects reported from isotretinoin treat- Activation of an infection trigger by isotretinoin therapy is complicat- ment include skeletal hyperostosis, calcification of tendons and ligaments, ed5. According to the Naranjo Probability Scale, there is a potential rela- premature epiphyseal closure, decreases in bone mineral density, back tionship between isotretinoin therapy and bilateral sacroiliitis6. It is thought pain, myalgia and arthralgia, transient pain in the chest, arthritis, tendonitis, that patients who are HLA-B27-positive could be more prone to develop- other types of bone abnormalities, elevations of creatine phosphokinase, ing sacroiliitis and back pain after treatment with isotretinoin, or that and rare reports of rhabdomyolysis.
    [Show full text]
  • Clinical Data Mining Reveals Analgesic Effects of Lapatinib in Cancer Patients
    www.nature.com/scientificreports OPEN Clinical data mining reveals analgesic efects of lapatinib in cancer patients Shuo Zhou1,2, Fang Zheng1,2* & Chang‑Guo Zhan1,2* Microsomal prostaglandin E2 synthase 1 (mPGES‑1) is recognized as a promising target for a next generation of anti‑infammatory drugs that are not expected to have the side efects of currently available anti‑infammatory drugs. Lapatinib, an FDA‑approved drug for cancer treatment, has recently been identifed as an mPGES‑1 inhibitor. But the efcacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib‑related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta‑analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta‑analyses. All the pain‑related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confdence intervals, and P values for the diferences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall efect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a signifcant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients.
    [Show full text]
  • Employees Calling About RTW Clearance
    1. Employee should do home quarantine for 7 days Employees calling and consult their physician about RTW clearance 2. Employee must call their own manager to call in Community/General Exposure OR sick as per their usual policy IP&C or Supervisor Confirmed Exposure 3. To return to work, employee must be fever-free without antipyretic for 3 days (72 hours) AND 1. Confirm that employee symptoms improveD AND finisheD 7-day home has finished 7-day home quarantine Community/General/ Travel/ quarantine AND fever-free Day Zero= First Day of Symptoms without antipyretics for 3 CDC Level 2/3 Country* COVID Permitted work on the 8th day days (72 hours) AND Exposure Employee must call the WHS hotline back symptoms have improved then for RTW clearance Employees who call-in 2. Employee should wear Community/General/ 4.Fill out RTW form to place employee off-duty with non-CLI surgical face mask during Unknown COVID Symptoms, but still entire shift while at work exposure (any not feeling well: going forward 3. If employee has been off- exposure that is NOT Please remember to stay duty for 8 or more calendar “Infection Prevention home if you don’t feel days, then email and Control (IP&C) well. Healthcare team confirmed) [email protected] Personnel must not work with doctor’s note simply sick. Follow usual steps stating that they sought for take sick day and care/treatment for COVID- contact their manager. Note: loss of smell/taste alone does If there are NO like symptoms ANY 4.Employee should update NOT constitute CLI per WHS No RTW form needed for symptoms following their manager COVID-19 Symptoms: guidelines Employees with NO non-CLI exposure or travel, 5.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Mechanical Low Back Pain Joshua Scott Will, DO; ​David C
    Mechanical Low Back Pain Joshua Scott Will, DO; David C. Bury, DO; and John A. Miller, DPT Martin Army Community Hospital, Fort Benning, Georgia Low back pain is usually nonspecific or mechanical. Mechanical low back pain arises intrinsically from the spine, interverte- bral disks, or surrounding soft tissues. Clinical clues, or red flags, may help identify cases of nonmechanical low back pain and prompt further evaluation or imaging. Red flags include progressive motor or sensory loss, new urinary retention or overflow incontinence, history of cancer, recent invasive spinal procedure, and significant trauma relative to age. Imaging on initial presentation should be reserved for when there is suspicion for cauda equina syndrome, malignancy, fracture, or infection. Plain radiography of the lumbar spine is appropriate to assess for fracture and bony abnormality, whereas magnetic resonance imaging is better for identifying the source of neurologic or soft tissue abnormalities. There are multiple treatment modalities for mechanical low back pain, but strong evidence of benefit is often lacking. Moderate evidence supports the use of nonsteroidal anti-inflammatory drugs, opioids, and topiramate in the short-term treatment of mechanical low back pain. There is little or no evidence of benefit for acetamin- ophen, antidepressants (except duloxetine), skeletal muscle relaxants, lidocaine patches, and transcutaneous electrical nerve stimulation in the treatment of chronic low back pain. There is strong evidence for short-term effectiveness and moderate-quality evidence for long-term effectiveness of yoga in the treatment of chronic low back pain. Various spinal manipulative techniques (osteopathic manipulative treatment, spinal manipulative therapy) have shown mixed benefits in the acute and chronic setting.
    [Show full text]
  • Diagnosis and Treatment of Lumbar Disc Herniation with Radiculopathy
    Y Lumbar Disc Herniation with Radiculopathy | NASS Clinical Guidelines 1 G Evidence-Based Clinical Guidelines for Multidisciplinary ETHODOLO Spine Care M NE I DEL I U /G ON Diagnosis and Treatment of I NTRODUCT Lumbar Disc I Herniation with Radiculopathy NASS Evidence-Based Clinical Guidelines Committee D. Scott Kreiner, MD Paul Dougherty, II, DC Committee Chair, Natural History Chair Robert Fernand, MD Gary Ghiselli, MD Steven Hwang, MD Amgad S. Hanna, MD Diagnosis/Imaging Chair Tim Lamer, MD Anthony J. Lisi, DC John Easa, MD Daniel J. Mazanec, MD Medical/Interventional Treatment Chair Richard J. Meagher, MD Robert C. Nucci, MD Daniel K .Resnick, MD Rakesh D. Patel, MD Surgical Treatment Chair Jonathan N. Sembrano, MD Anil K. Sharma, MD Jamie Baisden, MD Jeffrey T. Summers, MD Shay Bess, MD Christopher K. Taleghani, MD Charles H. Cho, MD, MBA William L. Tontz, Jr., MD Michael J. DePalma, MD John F. Toton, MD This clinical guideline should not be construed as including all proper methods of care or excluding or other acceptable methods of care reason- ably directed to obtaining the same results. The ultimate judgment regarding any specific procedure or treatment is to be made by the physi- cian and patient in light of all circumstances presented by the patient and the needs and resources particular to the locality or institution. I NTRODUCT 2 Lumbar Disc Herniation with Radiculopathy | NASS Clinical Guidelines I ON Financial Statement This clinical guideline was developed and funded in its entirety by the North American Spine Society (NASS). All participating /G authors have disclosed potential conflicts of interest consistent with NASS’ disclosure policy.
    [Show full text]
  • Chronic Pelvic Pain & Pelvic Floor Myalgia Updated
    Welcome to the chronic pelvic pain and pelvic floor myalgia lecture. My name is Dr. Maria Giroux. I am an Obstetrics and Gynecology resident interested in urogynecology. This lecture was created with Dr. Rashmi Bhargava and Dr. Huse Kamencic, who are gynecologists, and Suzanne Funk, a pelvic floor physiotherapist in Regina, Saskatchewan, Canada. We designed a multidisciplinary training program for teaching the assessment of the pelvic floor musculature to identify a possible muscular cause or contribution to chronic pelvic pain and provide early referral for appropriate treatment. We then performed a randomized trial to compare the effectiveness of hands-on vs video-based training methods. The results of this research study will be presented at the AUGS/IUGA Joint Scientific Meeting in Nashville in September 2019. We found both hands-on and video-based training methods are effective. There was no difference in the degree of improvement in assessment scores between the 2 methods. Participants found the training program to be useful for clinical practice. For both versions, we have designed a ”Guide to the Assessment of the Pelvic Floor Musculature,” which are cards with the anatomy of the pelvic floor and step-by step instructions of how to perform the assessment. In this lecture, we present the video-based training program. We have also created a workshop for the hands-on version. For more information about our research and workshop, please visit the website below. This lecture is designed for residents, fellows, general gynecologists,
    [Show full text]
  • Treating Lower-Back Pain How Much Bed Rest Is Too Much?
    ® Treating lower-back pain How much bed rest is too much? ack pain is one of the most common reasons why people visit the doctor. The good news is that the pain often goes Baway on its own, and people usually recover in a week or two. Many people want to stay in bed when their back hurts. For many years, getting bed rest was the normal advice. However, newer data have shown that there is little to no role for bed rest in the treatment of low back pain. Here’s why: Staying in bed won’t help you get better faster. If you’re in terrible pain, bed rest may not actually ease the pain, but increase it. Research suggests that if you find comfortable positions and move around sometimes, you may not need bed rest at all. Research shows that: • More than 48 hours of bed rest may actually increase pain, by increasing the stiffness of the • The sooner you start physical therapy or return spine and the muscles. to activities such as walking, the faster you are • Many people recover just as quickly without any likely to recover. Longer bed rest can lead to bed rest. slower recovery. Longer bed rest can lead to slower recovery. What can I do for the pain? When you don’t move and bend, you lose Most people with lower-back pain should apply muscle strength and flexibility. With bed rest, heat or ice. Some people can get pain relief you lose about 1 percent of your muscle from an over-the-counter anti-inflammatory strength each day.
    [Show full text]
  • Acute Low Back Pain
    Acute low back pain Key reviewers: Mr Chris Hoffman, Orthopaedic Surgeon, Mana Orthopaedics, Wellington Dr John MacVicar, Medical Director, Southern Rehab, Christchurch Key concepts: ■ Acute low back pain is common and most patients will recover fully within three months ■ Serious causes are rare and can be excluded with careful history and examination ■ Radiological studies are not required for acute low back pain in the absence of red flags ■ An exact diagnosis is often not possible, nor needed for management ■ Patients’ beliefs and attitudes warrant as much attention as the anatomical and pathological aspects of their condition ■ Fear about pain is a major determinant of disability and possible chronicity ■ Management should include reassurance, education and helping the patient stay active ■ Adequate analgesia is important to allow the patient www.bpac.org.nz keyword: lowbackpain to stay active 6 | BPJ | Issue 21 Acute low back pain is common and often relapsing Red Flags: ▪ Trauma Low back pain is discomfort, muscle tension or stiffness ▪ Unrelenting pain, or pain worse at night localised to the area around the lumbar spine. Back pain (supine) may radiate to the groin, buttocks or legs as referred somatic pain and may be associated with lumbar radicular ▪ Age <20 years, or new back pain age >50 pain such as sciatica. years ▪ History of cancer In any given year approximately one third of adults will ▪ Systemic symptoms suffer from low back pain and one third of these will seek help from a health practitioner.1 Most people with low ▪ IV drug use back pain self-treat with over-the-counter medications and ▪ Immunosuppression or steroids lifestyle changes.2 ▪ Widespread or progressive neurological deficit Low back pain is described as acute if present for less than six weeks, sub-acute between six weeks and three Serious causes of acute low back pain are rare months, and chronic if it continues for longer than three and include:6 months.
    [Show full text]